EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
Intrinsic Value
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. [ Read More ]
The intrinsic value of one EYPT stock under the Base Case scenario is 3.44 USD. Compared to the current market price of 20.67 USD, EyePoint Pharmaceuticals Inc is Overvalued by 83%.
Valuation Backtest
EyePoint Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling EYPT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Rising Revenues and Positive Clinical Trials
2023-Q4 Earnings Call
In the final quarter of 2023, the company witnessed a surge in total net revenue, achieving $14 million versus $10.5 million in the prior year's quarter. This growth primarily resulted from recognized deferred revenue from the licensing of the YUTIQ franchise. Meanwhile, operational expenses took a dive due to strategic exits from the commercial business. Even with a $14.1 million net loss, there's notable progress compared to the earlier $43.5 million loss. The company's cash reserve stands strong at $331.1 million, expected to sustain key Phase III clinical trials for wet AMD treatment, EYP-1901, through 2026. Positive clinical trial data is anticipated for their Phase II PAVIA trial in Q2 2024, with hopes high for EYP-1901’s potential to revolutionize wet AMD treatment.
Balance Sheet Decomposition
EyePoint Pharmaceuticals Inc
Current Assets | 344.8m |
Cash & Short-Term Investments | 331.1m |
Receivables | 805k |
Other Current Assets | 12.9m |
Non-Current Assets | 10.4m |
PP&E | 10.2m |
Other Non-Current Assets | 150k |
Current Liabilities | 63.3m |
Accounts Payable | 30.5m |
Accrued Liabilities | 17.5m |
Other Current Liabilities | 15.2m |
Non-Current Liabilities | 25.6m |
Other Non-Current Liabilities | 25.6m |
Earnings Waterfall
EyePoint Pharmaceuticals Inc
Revenue
|
46m
USD
|
Cost of Revenue
|
-4.6m
USD
|
Gross Profit
|
41.4m
USD
|
Operating Expenses
|
-116.5m
USD
|
Operating Income
|
-75.1m
USD
|
Other Expenses
|
4.3m
USD
|
Net Income
|
-70.8m
USD
|
Free Cash Flow Analysis
EyePoint Pharmaceuticals Inc
What is Free Cash Flow?
EYPT Profitability Score
Profitability Due Diligence
EyePoint Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
EyePoint Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
EYPT Solvency Score
Solvency Due Diligence
EyePoint Pharmaceuticals Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
EyePoint Pharmaceuticals Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EYPT Price Targets Summary
EyePoint Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for EYPT is 44.54 USD with a low forecast of 22.22 USD and a high forecast of 71.4 USD.
Ownership
EYPT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
EYPT Price
EyePoint Pharmaceuticals Inc
Average Annual Return | -22.41% |
Standard Deviation of Annual Returns | 45.27% |
Max Drawdown | -91% |
Market Capitalization | 1B USD |
Shares Outstanding | 49 830 800 |
Percentage of Shares Shorted | 16.01% |
EYPT News
Last Important Events
EyePoint Pharmaceuticals Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
EyePoint Pharmaceuticals Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Watertown, Massachusetts and currently employs 122 full-time employees. The company went IPO on 2005-01-27. The Company’s lead product candidate, EYP-1901, combines a bioerodible formulation of its Durasert technology with vorolanib, a tyrosine kinase inhibitor (TKI), which has demonstrated anti-VEGF activity. The firm has two commercial products, YUTIQ and DEXYCU. YUTIQ is a non-erodible intravitreal implant containing fluocinolone acetonide (FA) lasting for up to 36 months and is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. YUTIQ utilizes its Durasert sustained-release drug delivery technology platform. DEXYCU is an indicated for the treatment of post-operative ocular inflammation. DEXYCU utilizes its Verisome drug-delivery technology. The firm is also advancing YUTIQ 50, a six-month treatment for non-infectious uveitis affecting the posterior segment of the eye, one of the causes of blindness under a supplemental new drug application (sNDA) strategy.
Contact
IPO
Employees
Officers
The intrinsic value of one EYPT stock under the Base Case scenario is 3.44 USD.
Compared to the current market price of 20.67 USD, EyePoint Pharmaceuticals Inc is Overvalued by 83%.